Tirzepatide
SURMOUNT-OSA
Eli Lilly · Phase 3 · Completed · Enrollment 469
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide MTD_GPI1 | n/r | n/r | n/r | n/r |
| Placebo_GPI1 | n/r | n/r | n/r | n/r |
| Tirzepatide MTD_GPI2 | n/r | n/r | n/r | n/r |
| Placebo_GPI2 | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide MTD_GPI1: endpoint not reported
- Placebo_GPI1: endpoint not reported
- Tirzepatide MTD_GPI2: endpoint not reported
- Placebo_GPI2: endpoint not reported